News

Coeptis Therapeutics, Inc. announced entry into an exclusive license agreement with the University of Pittsburgh for the rights to a chimeric antigen receptor T cell (CAR T) technology…
Read More...

Clearmind Medicine Inc.  a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced it…
Read More...

Abpro, a biotech company with the mission of improving the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies, announced a strategic…
Read More...

Sesen Bio, Inc. and Carisma Therapeutics Inc. (Carisma), a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies,…
Read More...

Rocket Pharmaceuticals, Inc. a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with…
Read More...

CytoReason announced an extension of its multi-year partnership with Pfizer to use CytoReason’s artificial intelligence technology for Pfizer’s drug development programs. Under the…
Read More...

AVROBIO, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to AVR-RD-04, an investigational gene therapy for the treatment…
Read More...

Veranex, the only truly comprehensive, global, tech-enabled service provider dedicated to the medical technology industry, announced that it has acquired Medidee, a top MedTech…
Read More...

Gilead Sciences, Inc. announced the completion of the previously announced transaction to acquire MiroBio, a privately held U.K.-based biotechnology company focused on restoring immune…
Read More...

Advanced NanoTherapies, Inc., a privately-held medical device company committed to solving vascular disease's most significant challenges through the creative applications of…
Read More...

Repligen Corporation announced it has entered into a strategic partnership and exclusive license agreement with DRS Daylight Solutions to expand the use of mid-infrared (mid-IR)…
Read More...

BeiGene announced that England’s health technology assessment institute, the National Institute for Health and Care Excellence (NICE), has issued a final appraisal document (FAD)…
Read More...

GENFIT,  a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, announced it has entered into an exclusivity agreement…
Read More...

Roche announced that the European Commission (EC) approved Vabysmo (faricimab) for the treatment of neovascular or ‘wet’ age-related macular degeneration (nAMD) and visual impairment…
Read More...

Recommendation based on TACKLE Phase III treatment data showing reduced risk of severe COVID-19 or death AstraZeneca's Evusheld (tixagevimab and cilgavimab, formerly…
Read More...

bluebird bio, Inc. announced the U.S. Food and Drug Administration (FDA) has granted Accelerated Approval of SKYSONA (elivaldogene autotemcel), also known as eli-cel, to slow the…
Read More...

Bristol Myers Squibb announced that the European Commission (EC) has approved the fixed-dose combination of Opdualag (nivolumab and relatlimab) for the first-line treatment of advanced…
Read More...

NeuroBo Pharmaceuticals, Inc. and Dong-A ST Co., Ltd. announced that they have entered into a conditional exclusive license agreement for NeuroBo to develop and commercialize DA-1241…
Read More...

Caladrius Biosciences, Inc. and Cend Therapeutics, Inc. announced that the proposed merger of the two companies has closed following the approval of Caladrius’ stockholders on September…
Read More...

Gilead Sciences, Inc. announced updates to the World Health Organization’s (WHO) Therapeutics and COVID-19: living guideline, which now conditionally recommends Veklury (remdesivir) for…
Read More...